Exclusive Summary

• Targets a massive global endometriosis market affecting approximately 190 million diverse women with strong unmet clinical demand.
• The planned 2026 US FDA filing ensures top-tier cGMP quality, enabling rapid regulatory approvals across global emerging markets via reliance pathways.
• Represents a rare early-wave generic opportunity for the first oral GnRH antagonist, offering minimal competition and substantial cost advantages over the expensive originator.